Anavex Partners with Neuronetrix for Alzheimer’s Clinical Trial

Anavex Partners with Neuronetrix for Alzheimer’s Clinical Trial

senior guide memory lossA novel, potentially disease-modifying treatment for Alzheimer's disease is set to begin a Phase 2a clinical trial, designed to evaluate efficacy over a time frame of 6 months, across 7 study sites in Australia. ANAVEX 2-73, a pipeline product of Anavex Life Sciences Corp., will be partnering with a leader in neurotech, Neuronetrix, for their proprietary COGNISION™ System, a neuro-electrophysiological device that allows objective assessments that can effectively quantify and analyze cognitive biomarkers in the study's participants.

There are over 332,000 Alzheimer's patients in Australia alone, and at least 44 million worldwide. There is still no known cure for this neurodegenerative disease, and today's available treatments have only been successful with slowing disease progression. Without a breakthrough treatment soon, experts are expecting the number of Alzheimer's patients to increase to 135 million worldwide by the year 2050.

This multi-site adaptive study will examine key performance measures in 32 patients with mild to moderate Alzheimer's disease. With COGNISION's help, Anavex's researchers will h

Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *